ShehabaldinAlqalyoobiMD
Pulmonology • Greenville, NCCritical Care Medicine, Interstitial Lung Diseases
Assistant Professor of Medicine
Dr. Alqalyoobi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
521 Moye Blvd
Greenville, NC 27834Phone+1 252-744-1600Fax+1 252-744-1115
Education & Training
University of LouisvilleMS, Biostatistics, 2020 - 2023
University of California Davis HealthFellowship, Pulmonary Disease and Critical Care Medicine, 2016 - 2019
University of Missouri-Kansas City School of MedicineResidency, Internal Medicine, 2013 - 2016
Arabian Gulf University College of MedicineClass of 2009
Certifications & Licensure
NC State Medical License 2019 - 2025
CA State Medical License 2016 - 2019
MO State Medical License 2013 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
- National Board of EchocardiographyCritical Care Echocardiography (Diplomate)
Awards, Honors, & Recognition
- Outstanding Critical Care Medicine faculty member of the year The Brody School of Medicine at East Carolina University, 2024
- Outstanding Pulmonary disease faculty member of the year The Brody School of Medicine at East Carolina University, 2021
- California Thoracic Society Scholar award California Thoracic Society, 2019
- Join now to see all
Clinical Trials
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Start of enrollment: 2021 Jun 01
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) Start of enrollment: 2023 Oct 30
Publications & Presentations
PubMed
- Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis.Janelle Vu Pugashetti, John S Kim, Swaraj Bose, Ayodeji Adegunsoye, Angela L Linderholm
American Journal of Respiratory and Critical Care Medicine. 2024-09-01 - 124 citationsGlobal burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis...
Lancet. 2024-05-18 - Prediction Model Development and Evaluation: More Issues to Come.Shehabaldin Alqalyoobi
Chest. 2024-04-01
Journal Articles
- New Approved Medications for Idiopathic Pulmonary FibrosisAlqalyoobi S, Salzman G, Current Drug Therapy, 12/2015
Books/Book Chapters
Press Mentions
Plasma Biomarkers of Idiopathic Pulmonary Fibrosis May Predict SurvivalSeptember 26th, 2019
Professional Memberships
- Member
- Member
- Society of Critical Care MedicineMember
- American Federation for Medical ResearchMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
